Industry

DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Filtration: Global Markets” report has been added to ResearchAndMarkets.com’s offering. The global market for pharmaceutical filtration is expected to grow from $12 billion in 2025 and is projected to reach $20.3 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.1% during the forecast period of 2025 … [Read more…]

LAS VEGAS–(BUSINESS WIRE)–The MolinaCares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Nevada (“Molina”), provided grants to two local food banks to help address rising food insecurity across the state. The donations, totaling $187,000, were given to Three Square Food Bank serving Southern Nevada and Food Bank of Northern Nevada. Both organizations have seen a … [Read more…]

– PDUFA target action date of June 30, 2026 – – Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition – – Veligrotug now has both Priority Review and Breakthrough Therapy Designations, each following requests which included … [Read more…]

CADEMPINO, Switzerland–(BUSINESS WIRE)–#ClinicalTrial—Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–#immunotherapy–Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well … [Read more…]

WASHINGTON–(BUSINESS WIRE)–#congress–Today, Council for Citizens Against Government Waste (CCAGW) President Tom Schatz issued the following statement in response to the announcement of two proposed Center for Medicare and Medicaid Innovation (CMMI) models, “GLOBE” and “GUARD,” that seek to advance so-called ‘most favored nation’ (MFN) drug price controls: “CCAGW is disappointed to see the administration push … [Read more…]

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market (“Nasdaq”) from the NYSE American LLC (“NYSE American”). The Company expects that its common shares … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “ENT Disorder Treatment Market – Global Forecast 2025-2032” report has been added to ResearchAndMarkets.com’s offering. The ENT disorder treatment market is experiencing rapid transformation as organizations adopt new medical technologies and evolving care models to address complex clinical and operational challenges. Senior decision-makers are seeking strategies that enable both enhanced patient outcomes and … [Read more…]

Urges Board to Allow Shareholders to Have Their Final Say on This Ill-Conceived Transaction NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today responded to the fourth postponement of STAAR’s Special Meeting of … [Read more…]